Exploring the Prevalence and Risk Factors of MASLD in Patients with Newly Diagnosed Diabetes Mellitus: A Comprehensive Investigation
Open accessThe DOI matches its Crossref record; 34 of the 35 references it cites were found in a registry or an index.
Abstract
Background: Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) represents a growing concern in the context of metabolic disorders, particularly among individuals diagnosed with type 2 diabetes mellitus (T2DM). This study aimed to investigate the prevalence of MASLD among newly diagnosed T2DM patients and identify the risk factors for MASLD in this population. Methods: This prospective study included 128 patients with newly diagnosed T2DM between January 2022 and June 2023. Demographic, clinical, anthropometric (BMI, waist circumference), and laboratory data (glucose, HbA1c, lipid profile, ALT, AST, creatinine, platelet count) were collected. MASLD was diagnosed based on ultrasonographic evidence of hepatic steatosis with at least one cardiometabolic risk factor after excluding other causes. Linear regression models were used to determine independent predictors. Results: MASLD was detected in 80.4% of patients. Compared with the MASLD (−) group, the MASLD (+) group had significantly higher ALT (47.1 ± 23 U/L vs. 24.9 ± 8 U/L, p < 0.001) and non-HDL cholesterol (189 ± 57 mg/dL vs. 167 ± 28 mg/dL, p = 0.047). Spearman correlation showed positive associations of MASLD severity with waist circumference, LDL cholesterol, and platelet count. ALT and BMI were independently associated with MASLD in linear regression analysis. Conclusions: This study underscores the significant prevalence of MASLD in newly diagnosed T2DM patients, emphasizing the relevance of early detection in addressing this common comorbidity in the diabetic population.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s002 · Cited by 4,792 · cited 1×
“Each patient’s diagnosis of T2DM was confirmed by an internal medicine specialist using the diagnostic criteria of the American Diabetes Association [10].”
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
Rinella, M. E., Lazarus, J. V., Ratziu, V., Francque, S. M., Sanyal, A. J., Kanwal, F., Romero, D., Abdelmalek, M. F., Anstee, Q. M., Arab, J. P., et al. (2023) · Hepatology · doi:10.1097/hep.0000000000000520 · Cited by 3,476 · cited 3×
“MASLD is often associated with morbidities such as obesity, insulin resistance, T2DM, metabolic syndrome (MetS), hyperlipidemia (dyslipidemia), and cardiovascular diseases (CVD) [12,19].”
Angulo, P., Hui, J. M., Marchesini, G., Bugianesi, E., George, J., Farrell, G. C., Enders, F., Saksena, S., Burt, A. D., Bida, J. P., et al. (2007) · Hepatology · doi:10.1002/hep.21496 · Cited by 3,203 · cited 1×
“Age; BMI; DM status; AST, ALT, and albumin levels; and platelet count are used when calculating these scoring systems [26,27].”
2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2021
American Diabetes Association (2021) · Diabetes Care · doi:10.2337/dc21-s002 · Cited by 3,116 · cited 1×
“…(i) fasting plasma glucose level ≥ 126 mg/dL, (ii) 2 h plasma glucose level ≥ 200 mg/dL during a 75 g oral glucose tolerance test, (iii) random plasma glucose ≥ 200 mg/dL in a patient exhibiting classic symptoms of hyperglycemia or hyperglycemic crisis, (iv) hemoglobin A1c (HbA1c) level ≥ 6.5 [11].”
InfluentialByrne, C. D., & Targher, G. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2014.12.012 · Cited by 3,042 · cited 1×
“These processes collectively increase the risk of developing or worsening T2DM [12,28,29].”
Comparison of Noninvasive Markers of Fibrosis in Patients With Nonalcoholic Fatty Liver Disease
Shah, A. G., Lydecker, A., Murray, K., Tetri, B. N., Contos, M. J., & Sanyal, A. J. (2009) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2009.05.033 · Cited by 1,553 · cited 1×
“Age; BMI; DM status; AST, ALT, and albumin levels; and platelet count are used when calculating these scoring systems [26,27].”
The integrative biology of type 2 diabetes
Roden, M., & Shulman, G. I. (2019) · Nature · doi:10.1038/s41586-019-1797-8 · Cited by 1,167 · cited 1×
“Type 2 diabetes mellitus (T2DM) is a prevalent and complex metabolic disorder associated with various complications, which significantly impact public health [1].”
Tilg, H., Moschen, A. R., & Roden, M. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2016.147 · Cited by 1,002 · cited 1×
“Mitochondrial dysfunction, cytokines, lipotoxins, and adipocytokines play an important role in both MASLD and T2DM [30].”
Non alcoholic fatty liver disease and metabolic syndrome.
Paschos, P., & Paletas, K. (2009) · PubMed Central · Cited by 718
Nonalcoholic fatty liver disease: A precursor of the metabolic syndrome
Lonardo, A., Ballestri, S., Marchesini, G., Angulo, P., & Loria, P. (2015) · Digestive and Liver Disease · doi:10.1016/j.dld.2014.09.020 · Cited by 685 · cited 1×
“In a systemic review by Lonardo et al., the incidence rate of MASLD in individuals with T2DM was found to range from 50% to 75%, varying according to ethnicity among the studies [21].”
NAFLD as a Continuum: From Obesity to Metabolic Syndrome and Diabetes
Godoy-Matos, A. F., Silva Júnior, W. S., & Valerio, C. M. (2020) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-020-00570-y · Cited by 643
Pathogenesis of Nonalcoholic Steatohepatitis
Machado, M. V., & Diehl, A. M. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.02.066 · Cited by 539 · cited 1×
“MASLD is characterized by hepatic steatosis in the presence of cardiometabolic risk factors and, by definition, it excludes other causes of liver fat accumulation such as excessive alcohol consumption or viral hepatitis [3,4].”
Non-alcoholic fatty liver disease and diabetes
Hazlehurst, J. M., Woods, C., Marjot, T., Cobbold, J. F., & Tomlinson, J. W. (2016) · Metabolism · doi:10.1016/j.metabol.2016.01.001 · Cited by 527 · cited 1×
“While the presence of T2DM can cause progression to MASLD or fibrosis, MASLD also leads to worsening of the natural course of diabetic complications (both micro and macrovascular) in T2DM patients [33].”
From NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options
Gastaldelli, A., & Cusi, K. (2019) · JHEP Reports · doi:10.1016/j.jhepr.2019.07.002 · Cited by 455 · cited 1×
“T2DM and MASLD affect each other’s course as well as increase the risk of development of the other via a common pathophysiological mechanism [32].”
Detection of Significant Coronary Artery Disease by Noninvasive Anatomical and Functional Imaging
Neglia, D., Rovai, D., Caselli, C., Pietila, M., Teresinska, A., Aguadé-Bruix, S., Pizzi, M. N., Todiere, G., Gimelli, A., Schroeder, S., et al. (2015) · Circulation: Cardiovascular Imaging · doi:10.1161/circimaging.114.002179 · Cited by 423
En Li Cho, E., Ang, C. Z., Quek, J., Fu, C. E., Lim, L. K. E., Heng, Z. E. Q., Tan, D. J. H., Lim, W. H., Yong, J. N., Zeng, R., et al. (2023) · Gut · doi:10.1136/gutjnl-2023-330110 · Cited by 380
Non-Alcoholic Fatty Liver Disease and the Metabolic Syndrome
Najjar, S. M. (2011) · Metabolic Basis of Obesity · doi:10.1007/978-1-4419-1607-5_12 · Cited by 354
Liver fat imaging—a clinical overview of ultrasound, CT, and MR imaging
Zhang, Y. N., Fowler, K. J., Hamilton, G., Cui, J. Y., Sy, E. Z., Balanay, M., Hooker, J. C., Szeverenyi, N., & Sirlin, C. B. (2018) · The British Journal of Radiology · doi:10.1259/bjr.20170959 · Cited by 304 · cited 1×
“…in echogenicity is observed; grade 2—moderate increase in echogenicity, accompanied by a reduction in the visibility of the portal vein wall and diaphragm; and grade 3—increase in echogenicity, leading to the invisibility of the portal vein wall, diaphragm, and posterior part of the liver [13].”
Classification, Differential Diagnosis, and Staging of Diabetic Peripheral Neuropathy
Thomas, P. (1997) · Diabetes · doi:10.2337/diab.46.2.s54 · Cited by 280 · cited 1×
“Recording electrodes [15] were used to record motor signals and ring electrodes were used to record sensory nerve signals that were transmitted antidromically [16].”
Non-alcoholic fatty liver disease: Definition and subtypes
Han, S. K., Baik, S. K., & Kim, M. Y. (2023) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2022.0424 · Cited by 245 · cited 1×
“The acknowledgment of MASLD as the predominant cause of chronic liver disease has been steadily growing, with a prevalence reaching up to 30% [5,6].”
Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus
Dharmalingam, M., & Yamasandhi, P. (2018) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_585_17 · Cited by 239 · cited 1×
“The prevalence of MASLD is higher in the group with metabolic diseases than in the general population, and MASLD is detected in 56–70% of the patients with T2DM [19,20].”
Gehrke, N., & Schattenberg, J. M. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.02.020 · Cited by 209 · cited 1×
“It may also contribute to systemic inflammation and overall metabolic health problems [8].”
Chang, Y., Jung, H.-S., Yun, K. E., Cho, J., Cho, Y. K., & Ryu, S. (2013) · American Journal of Gastroenterology · doi:10.1038/ajg.2013.349 · Cited by 163 · cited 1×
“The acknowledgment of MASLD as the predominant cause of chronic liver disease has been steadily growing, with a prevalence reaching up to 30% [5,6].”
Diabetic retinopathy: clinical findings and management.
Viswanath, K., & McGavin, D. D. M. (2003) · PubMed · Cited by 133
Tsochatzis, E., Coilly, A., Nadalin, S., Levistky, J., Tokat, Y., Ghobrial, M., Klinck, J., & Berenguer, M. (2019) · Transplantation · doi:10.1097/tp.0000000000002433 · Cited by 105 · cited 1×
“These processes collectively increase the risk of developing or worsening T2DM [12,28,29].”
Diabetic nephropathy; principles of diagnosis and treatment of diabetic kidney disease.
Nazar, C. M. J. (2014) · PubMed Central · Cited by 74
Nonalcoholic Fatty Liver Disease and Cardiovascular Disease
Przybyszewski, E. M., Targher, G., Roden, M., & Corey, K. E. (2021) · Clinical Liver Disease · doi:10.1002/cld.1017 · Cited by 74 · cited 1×
“Patients with MASLD have a higher mortality rate than the general population, and the primary cause of death in these patients is cardiovascular disease [9,18].”
Redefining non-alcoholic fatty liver disease: what's in a name?
Hepatology, T. L. G. (2020) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(20)30091-1 · Cited by 55 · cited 1×
“MASLD is characterized by hepatic steatosis in the presence of cardiometabolic risk factors and, by definition, it excludes other causes of liver fat accumulation such as excessive alcohol consumption or viral hepatitis [3,4].”
Challenges in the celiac disease diagnosis; Prague consensus.
Dashatan, N. A., Koushki, M., Motedayen, M., Dousti, M., Sayehmiri, F., Vafaee, R., Norouzinia, M., & Gholami, R. (2017) · PubMed Central · Cited by 47
Establishment of a Risk Prediction Model for Non-alcoholic Fatty Liver Disease in Type 2 Diabetes
Zhang, Y., Shi, R., Yu, L., Ji, L.-P., Li, M., & Hu, F. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00893-z · Cited by 43 · cited 1×
“In a study involving 874 patients with T2DM, sex, age, total cholesterol level, BMI, waist circumference, diastolic blood pressure, serum uric acid level, duration of illness, and HDL cholesterol level were identified as independent predictors of the development of MASLD [25].”
Non-Alcoholic Fatty Liver Disease or Type 2 Diabetes Mellitus—The Chicken or the Egg Dilemma
Kosmalski, M., Śliwińska, A., & Drzewoski, J. (2023) · Biomedicines · doi:10.3390/biomedicines11041097 · Cited by 42 · cited 1×
“Among the comorbidities linked with T2DM, Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) has emerged as a noteworthy condition [2].”
Metabolic dysfunction-associated fatty liver disease: current therapeutic strategies
Al-Hashmi, K., Giglio, R. V., Stoian, A. P., Patti, A. M., Waili, K. A., Al‐Rasadi, K., Ciaccio, M., & Rizzo, M. (2024) · Frontiers in Nutrition · doi:10.3389/fnut.2024.1355732 · Cited by 42 · cited 2×
“Patients with MASLD have a higher mortality rate than the general population, and the primary cause of death in these patients is cardiovascular disease [9,18].”
Hamid, S. S., Butt, A. S., Sharif, F., Haider, Z., Salih, M., Awan, S., Khan, A. A., & Akhter, J. (2019) · Euroasian Journal of Hepato-Gastroenterology · doi:10.5005/jp-journals-10018-1288 · Cited by 18
Oliveros-Montiel, A., Santos‐López, G., & Sedeño-Monge, V. (2020) · PubMed · Cited by 4
Research works printed but not linked: 1
- Atan N.A.D. Koushki M. Motedayen M. Dousti M. Sayehmiri F. Vafaee R. Norouzinia M. Gholami R. Type 2 diabetes mellitus and non-alcoholic fatty liver disease: A systematic review and meta-analysis Gastroenterol. Hepatol. Bed. Bench. 2017 10 (Suppl. S11) S1 S7 29511464 PMC5838173
Cited by
PPARs in molecular pathogenesis and drug treatment of type 2 diabetes-related MASLD
Lonardo, A., & Weiskirchen, R. (2025) · Exploration of Digestive Diseases · doi:10.37349/edd.2025.100590 · Cited by 7
The HepG2 Cell Line as a Model for Studying Metabolic Dysfunction-Associated Steatotic Liver Disease
Kotlyarova, A., Iskrina, A., & Kotlyarov, S. (2026) · International journal of molecular sciences · doi:10.3390/ijms27083399 · Cited by 10
Raina, M. A., Bhutani, K., Rashid, G., Khan, M., & Mudassar, S. (2026) · Indian Journal of Clinical Biochemistry · doi:10.1007/s12291-026-01427-3 · Cited by 1
Qu, X., Li, G. X., Tao, H., Ye, X., Huang, J., Chen, Q. W., Xu, J. Y., Jiang, M., Jia, W., & Xie, Q. (2026) · Cardiovascular Diabetology · doi:10.1186/s12933-026-03205-0 · Cited by 1
“…one of the following conditions: (1) presence of viral hepatitis, including HBV, HCV, and HEV ( N = 75) and Acute based on the 2023 international multi-society consensus criteria, requiring the presence of hepatic steatosis via ultrasonography in combination with type 2 diabetes mellitus [38–40].”
Котлярова, А. А., & Kotlyarov, S. N. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27104453 · Cited by 1
Metadata
- Authors
- Beyazal Polat, H., Beyazal, M., Arpa, M., Kızılkaya, B., Ayaz, T., Gündoğdu, Ö. L., Konur, K., Polat, Z., Beyazal Çeliker, F., & Atasoy, H.
- Affiliations
- Recep Tayyip Erdoğan University Faculty of Medicine, 53100 Rize, Türkiye
- Recep Tayyip Erdoğan University (TR)
- Rize Chambers and Commodity Exchanges Union Science High School, 53020 Rize, Türkiye
- ORCID
- Venue
- Journal of Clinical Medicine
- Publisher
- MDPI AG
- Published
- 2025-05-17
- Volume
- 14
- Issue
- 10
- Pages
- 3513
- ISSN
- 2077-0383 (ISSN-L)
- PMC
- PMC12112127
- OpenAlex
- W4410501420
- Cited by
- 13
- References
- 35
- Citations by year
- 2026: 12 · 2025: 1
- FWCI
- 9.01
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal of Clinical Medicine (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Keywords
- non-alcoholic fatty liver disease, type 2 diabetes, newly diagnosed diabetes, prevalence, risk factors, hepatic steatosis, ALT, non-HDL cholesterol, waist circumference, body mass index, platelet count, LDL cholesterol, comorbidities
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.